PMID- 38012715 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231129 IS - 2162-3619 (Print) IS - 2162-3619 (Electronic) IS - 2162-3619 (Linking) VI - 12 IP - 1 DP - 2023 Nov 27 TI - Deciphering tumor-infiltrating dendritic cells in the single-cell era. PG - 97 LID - 10.1186/s40164-023-00459-2 [doi] LID - 97 AB - Dendritic cells (DCs) serve as a pivotal link connecting innate and adaptive immunity by processing tumor-derived antigens and activating T cells. The advent of single-cell sequencing has revolutionized the categorization of DCs, enabling a high-resolution characterization of the previously unrecognized diversity of DC populations infiltrating the intricate tumor microenvironment (TME). The application of single-cell sequencing technologies has effectively elucidated the heterogeneity of DCs present in the tumor milieu, yielding invaluable insights into their subpopulation structures and functional diversity. This review provides a comprehensive summary of the current state of knowledge regarding DC subtypes in the TME, drawing from single-cell studies conducted across various human tumors. We focused on the categorization, functions, and interactions of distinct DC subsets, emphasizing their crucial roles in orchestrating tumor-related immune responses. Additionally, we delve into the potential implications of these findings for the identification of predictive biomarkers and therapeutic targets. Enhanced insight into the intricate interplay between DCs and the TME promises to advance our comprehension of tumor immunity and, in turn, pave the way for the development of more efficacious cancer immunotherapies. CI - (c) 2023. The Author(s). FAU - Huang, Qingyu AU - Huang Q AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. FAU - Wang, Fuhao AU - Wang F AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. FAU - Hao, Di AU - Hao D AD - The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, China. FAU - Li, Xinyu AU - Li X AD - The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, China. FAU - Li, Xiaohui AU - Li X AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. FAU - Lei, Tianyu AU - Lei T AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. FAU - Yue, Jinbo AU - Yue J AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. jbyue@sdfmu.edu.cn. FAU - Liu, Chao AU - Liu C AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. charles.liu@whu.edu.cn. LA - eng GR - Grant No. 82272753/National Natural Science Foundation of China/ GR - Grant No. 2019RC003/Young TaiShan Scholars and Academic Promotion Program of Shandong First Medical University/ GR - ZR2021LZL002/Shandong Provincial Natural Science Foundation/ GR - ZR2021QH006/Shandong Provincial Natural Science Foundation/ GR - flzh202103/Bethune Cancer Radiotherapy Translational Medicine Research Fund/ GR - flzh202118/Beijing Bethune Charitable Foundation/ PT - Journal Article PT - Review DEP - 20231127 PL - England TA - Exp Hematol Oncol JT - Experimental hematology & oncology JID - 101590676 PMC - PMC10680280 OTO - NOTNLM OT - Dendritic cells OT - Immunotherapy OT - Single-cell sequencing technologies OT - Tumor microenvironment COIS- The authors declare that they have no competing interests. EDAT- 2023/11/28 06:42 MHDA- 2023/11/28 06:43 PMCR- 2023/11/27 CRDT- 2023/11/28 00:11 PHST- 2023/07/10 00:00 [received] PHST- 2023/11/14 00:00 [accepted] PHST- 2023/11/28 06:43 [medline] PHST- 2023/11/28 06:42 [pubmed] PHST- 2023/11/28 00:11 [entrez] PHST- 2023/11/27 00:00 [pmc-release] AID - 10.1186/s40164-023-00459-2 [pii] AID - 459 [pii] AID - 10.1186/s40164-023-00459-2 [doi] PST - epublish SO - Exp Hematol Oncol. 2023 Nov 27;12(1):97. doi: 10.1186/s40164-023-00459-2.